Optimi Health Corp.

Optimi Health Corp. IPO - Plain English Investor Guide

Hey there! Thinking about investing in Optimi Health’s IPO? Here’s what you need to know:

1. What Does Optimi Health Do?

• They’re a Health Canada-licensed drug maker focused on psychedelic medicines like MDMA (medical-grade "ecstasy") and psilocybin (the active ingredient in magic mushrooms).
• Operate two high-tech labs in British Columbia featuring:
  • 🌱 Climate-controlled mushroom grow rooms
  • 🔒 Bank vault-level drug storage (Level 8 security)
  • 🧪 In-house quality testing labs
  • 🏭 Ultra-clean manufacturing suites (meeting strict medical standards)
• Already selling internationally: Supplies MDMA/psilocybin to Australia under special licenses.
• Clinical trials underway:
  • Psilocybin in late-stage testing (Phase 2b) in Canada
  • MDMA in Phase 2 trials in Israel

2. How Do They Make Money?

• 2024 Revenue (as of Sept 30): C$389,850 (~US$286,233)
  • 97% from supplements: Wellness products like mushroom vitamins (C$378,824)
  • 3% from drugs: First-ever psychedelic medicine sales (C$11,026)
• Reality check: Total revenue is less than a typical Canadian dentist office earns annually.

3. What’s the Cash Situation?

The company didn’t provide much detail about their current cash reserves or expenses in their latest filing.

4. IPO Cash Use

Optimi hasn’t shared specific plans for how they’ll use IPO funds. This lack of clarity might be something to consider.

5. Biggest Risks

• 🌍 Regulatory Hurdles: Must win country-by-country approvals (only Australia cleared so far).
• ⚙️ Unproven Automation: Profit plans rely on experimental tech – like betting on self-checkout machines that might fail.
• 🧪 No Patents: Recipes protected like KFC’s secret formula – one leak could help competitors.
• 🚚 Supply Chain Issues: Key MDMA ingredients are hard to source (like baking during a flour shortage).
• 📉 Supplement Reliance: 97% of sales come from non-drug products. A regulatory crackdown could wipe out their main income.

Final Thoughts for Investors

✅ The Good:

• Real product sales in Australia prove they can deliver
• High-security labs show serious infrastructure
• Active clinical trials could open new markets

⚠️ The Concerns:

• Tiny revenue with heavy reliance on non-drug sales
• Major regulatory and legal unknowns
• Critical details missing about expenses and IPO fund use

💡 Decision Tip: If interested, review pages 66+ of their prospectus for automation plans and supply chain risks. Ask your broker: "How does Optimi’s risk profile compare to other pharma IPOs?"

Important Note:
Optimi’s IPO filing lacks CEO bios, expense breakdowns, and clear plans for IPO cash – unusual omissions that investors should consider.

This isn’t financial advice! Always do your own research or consult a pro.

Need More? Request the full prospectus through your brokerage account.